Myocardial InjuryNCT06287372
Comparison of Changes in Intra-myocardial Amino Acids During Use of Calafiore and Modified Del Nido Cardioplegia
An observational study of Myocardial Injury and Cardiac Surgery, run by Damascus University at 1 site in Syria.
Trial summary
The aim of the present study was to investigate intra-operative changes in markers of myocardial injury and myocardial intracellular amino acids during ischemia and reperfusion, comparing two methods of myocardial protection; Calafiore intermittent antegrade warm blood cardioplegia or modified del Nido intermittent… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Myocardial Injury, Cardiac Surgery, Myocardial Protection
- What is being tested?
- Cardioplegic solution
- How many people
- 20 participants
- Where
- 1 siteSyria
- Study dates
- 4 Jul 2022to 4 Jul 2023
- How long will I take part?
- 7 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Twenty consecutive patients undergoing elective primary coronary artery bypass grafting were enrolled in this study
Who may be able to join
- All consecutive patients undergoing elective primary coronary artery bypass grafting were enrolled in this study.
Who cannot join
- Patients were excluded from this study if they had suffered from previous myocardial infarction, had reduced ejection fraction or were undergoing combined or repeated surgery.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparison of Changes in Intra-myocardial Amino Acids During Use of Calafiore and Modified Del Nido Cardioplegic Solutions in Routine Coronary Artery Bypass Surgery
The aim of the present study was to investigate intra-operative changes in markers of myocardial injury and myocardial intracellular amino acids during ischemia and reperfusion, comparing two methods of myocardial protection; Calafiore intermittent antegrade warm blood cardioplegia or modified del Nido intermittent antegrade cold blood cardioplegia in routine coronary artery bypass grafting procedures.
Read the detailed description
Twenty consecutive patients undergoing elective primary coronary artery bypass grafting were enrolled in this study. Patients were excluded from this study if they had suffered from previous myocardial infarction, had reduced ejection fraction or were undergoing combined or repeated surgery. Patients were randomly assigned to undergo surgery using one of two methods for myocardial protection:
- Group 1: Calafiore intermittent antegrade warm blood cardioplegia (consisting of normothermic pump blood, potassium chloride 2 mEq/ml and magnesium sulfate 50%). This cardioplegic solution was administered at 37 degrees C following application of the aortic cross-clamp and repeated after completion of each distal coronary anastomosis as described previously.
- Group 2: Modified del Nido intermittent antegrade cold blood cardioplegic solution (consisting of 750 ml of lactated Ringer solution, 200 ml of pump blood, 13 ml of sodium bicarbonate 8.4%, 16 ml of mannitol 20%, 4 ml of magnesium sulfate 50%, 13 ml of lidocaine 2% and 13 ml of potassium chloride 2 mEq/ml). This solution was administered as a 1-liter bolus at 3-4 degrees C following application of the aortic cross-clamp, and repeated as a 500 ml bolus if cross-clamp time extended beyond 60 minutes (none of the patients in this study).
Each patient enrolled in the study gave a written informed consent for the publication of the study data, and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the local human research committee number 171 dated 13 April 2022
Collection of blood samples and myocardial biopsies Peripheral blood samples were collected immediately prior to surgery and at 4, 12, 24 and 48 hours postoperatively and were used for determination of blood concentrations of cardiac enzymes (CK-MB and troponin I).
Myocardial biopsies (4-14 mg wet weight) were taken using a Tru-cut needle from the apex of the left ventricle in every patient as follows:
- Biopsy 1: "Resting specimen", immediately after beginning of extracorporeal circulation.
- Biopsy 2: "Ischemic specimen", 30 minutes after application of the aortic cross-clamp.
- Biopsy 3: "Reperfusion specimen", 20 minutes following the removal of aortic cross-clamp.
Each specimen was immediately snap-frozen in liquid nitrogen (-185 degrees C) until processing for the analyses of amino acids and lactic acid.
Determination of cardiac enzymes (CK-MB and troponin I) Analyses were carried out using an immunofluorescence scanner (iChroma II, Boditech Med Incorporated, Korea and Obelis s.a, Belgium). Blood levels of CK-MB were expressed as mg/dl and levels of troponin I were expressed as ng/ml.
Determination of myocardial amino acid and lactic acid concentrations Each frozen biopsy specimen was weighed (Laboratory Analytical Balance, Sartorius, Germany), crushed in liquid nitrogen and homogenized in 1000 micro mol of 0.9% normal saline. A 400 micro mol sample of the homogenate was transferred to an Eppendorf tube and 100 micro mol of HPLC water was added. Each sample was then stored at 4 degrees C for one hour, after which it was centrifuged at 10000 round/min for 5 minutes. A 400 micro mol sample of the supernatant was filtered through a Vivaspin® 500 membrane filter 0.2 µm (Satorius, Germany), transferred to an Eppendorf tube and was centrifuged at 10000 round/min for 5 minutes. A 300 micro mol sample of the filtrate was transferred to an Eppendorf tube and an equal volume of sample dilution buffer (membraPure, Germany) was added. This solution was used for determining the concentrations of 7 amino acids (alanine, glutamine, glutamic acid, glycine, lysine, ornithine and taurine) using the A300 Amino Acid Analyzer (ARACUS, membraPure, Germany). Lactic acid concentrations were also measured using a dedicated plasma lactate determination kit and analyzer (LACT2, cobas, Roche Diagnostics GmbH, Germany). Concentrations of amino acids and lactic acid were expressed as micro mol/g wet weight.
- Conditions
- Myocardial Injury, Cardiac Surgery, Myocardial Protection
- Being tested
- Cardioplegic solution
- Keywords
- cardioplegia, coronary artery bypass grafting, amino acid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cardioplegic solutionOther
Patients were randomly assigned to undergo surgery using one of two methods for myocardial protection
| Study group | Role | What they receive |
|---|---|---|
| Group 1: Calafiore cardioplegia | Patients were randomly assigned to undergo surgery using one of two methods for myocardial protection:
• Group 1: Calafiore intermittent antegrade warm blood cardioplegia (consisting of normothermic pump blood, potassium chloride 2 mEq/ml and magnesium sulfate 50%). This cardioplegic solution was administered at 37 degrees C following application of the aortic cross-clamp and repeated after completion of each distal coronary anastomosis as described previously. Receives: Other: Cardioplegic solution | |
| Group 2: del Nido cardioplegia | • Group 2: Modified del Nido intermittent antegrade cold blood cardioplegic solution (consisting of 750 ml of lactated Ringer solution, 200 ml of pump blood, 13 ml of sodium bicarbonate 8.4%, 16 ml of mannitol 20%, 4 ml of magnesium sulfate 50%, 13 ml of lidocaine 2% and 13 ml of potassium chloride 2 mEq/ml). This solution was administered as a 1-liter bolus at 3-4 degrees C following application of the aortic cross-clamp, and repeated as a 500 ml bolus if cross-clamp time extended beyond 60 minutes (none of the patients in this study). Receives: Other: Cardioplegic solution |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in markers of myocardial injury
Changes in release of myocardial CK-MB and troponin I
Measured: 4, 12, 24 and 48 hours postoperatively
Secondary outcomes (1)
Changes in myocardial amino acid concentrations
Changes in myocardial intracellular concentrations of 7 amino acids (alanine, glutamine, glutamic acid, glycine, lysine, ornithine and taurine)
Measured: 2-3 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Mar 2024
- Study start4 Jul 2022
- Primary completion4 Jul 2023
- Study completion4 Jul 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myocardial InjuryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 20 participants (actual)
- Target duration
- 7 Days
Sponsor and investigators
- Lead sponsor
- Damascus University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Mohammad Bashar Izzat, Study director, Damascus University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06287372
- Sponsor's protocol ID
- 3261
- Status last verified
- Mar 2026
- First submitted
- 23 Feb 2024
- Last updated
- 19 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Data will be uploaded on (figshare) data repository site
Study at a glance
From the registry record, last updated by the sponsor on 19 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Changes in Intra-myocardial Amino Acids During Use of Calafiore and Modified Del Nido Cardioplegic Solutions in Routine Coronary Artery Bypass Surgery
- ClinicalTrials.gov ID
- NCT06287372
- Acronym / sponsor ID
- 3261
- Conditions
- Myocardial Injury, Cardiac Surgery, Myocardial Protection
- Keywords
- cardioplegia, coronary artery bypass grafting, amino acid
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Damascus UniversityUniversity, hospital or other
- Study start
- 4 Jul 2022 (actual)
- Primary completion
- 4 Jul 2023 (actual)
- Study completion
- 4 Jul 2023 (actual)
- First posted
- 1 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the present study was to investigate intra-operative changes in markers of myocardial injury and myocardial intracellular amino acids during ischemia and reperfusion, comparing two methods of myocardial protection; Calafiore intermittent antegrade warm blood cardioplegia or modified del Nido intermittent antegrade cold blood cardioplegia in routine coronary artery bypass grafting procedures.
Detailed description
Twenty consecutive patients undergoing elective primary coronary artery bypass grafting were enrolled in this study. Patients were excluded from this study if they had suffered from previous myocardial infarction, had reduced ejection fraction or were undergoing combined or repeated surgery. Patients were randomly assigned to undergo surgery using one of two methods for myocardial protection:
- Group 1: Calafiore intermittent antegrade warm blood cardioplegia (consisting of normothermic pump blood, potassium chloride 2 mEq/ml and magnesium sulfate 50%). This cardioplegic solution was administered at 37 degrees C following application of the aortic cross-clamp and repeated after completion of each distal coronary anastomosis as described previously.
- Group 2: Modified del Nido intermittent antegrade cold blood cardioplegic solution (consisting of 750 ml of lactated Ringer solution, 200 ml of pump blood, 13 ml of sodium bicarbonate 8.4%, 16 ml of mannitol 20%, 4 ml of magnesium sulfate 50%, 13 ml of lidocaine 2% and 13 ml of potassium chloride 2 mEq/ml). This solution was administered as a 1-liter bolus at 3-4 degrees C following application of the aortic cross-clamp, and repeated as a 500 ml bolus if cross-clamp time extended beyond 60 minutes (none of the patients in this study).
Each patient enrolled in the study gave a written informed consent for the publication of the study data, and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the local human research committee number 171 dated 13 April 2022
Collection of blood samples and myocardial biopsies Peripheral blood samples were collected immediately prior to surgery and at 4, 12, 24 and 48 hours postoperatively and were used for determination of blood concentrations of cardiac enzymes (CK-MB and troponin I).
Myocardial biopsies (4-14 mg wet weight) were taken using a Tru-cut needle from the apex of the left ventricle in every patient as follows:
- Biopsy 1: "Resting specimen", immediately after beginning of extracorporeal circulation.
- Biopsy 2: "Ischemic specimen", 30 minutes after application of the aortic cross-clamp.
- Biopsy 3: "Reperfusion specimen", 20 minutes following the removal of aortic cross-clamp.
Each specimen was immediately snap-frozen in liquid nitrogen (-185 degrees C) until processing for the analyses of amino acids and lactic acid.
Determination of cardiac enzymes (CK-MB and troponin I) Analyses were carried out using an immunofluorescence scanner (iChroma II, Boditech Med Incorporated, Korea and Obelis s.a, Belgium). Blood levels of CK-MB were expressed as mg/dl and levels of troponin I were expressed as ng/ml.
Determination of myocardial amino acid and lactic acid concentrations Each frozen biopsy specimen was weighed (Laboratory Analytical Balance, Sartorius, Germany), crushed in liquid nitrogen and homogenized in 1000 micro mol of 0.9% normal saline. A 400 micro mol sample of the homogenate was transferred to an Eppendorf tube and 100 micro mol of HPLC water was added. Each sample was then stored at 4 degrees C for one hour, after which it was centrifuged at 10000 round/min for 5 minutes. A 400 micro mol sample of the supernatant was filtered through a Vivaspin® 500 membrane filter 0.2 µm (Satorius, Germany), transferred to an Eppendorf tube and was centrifuged at 10000 round/min for 5 minutes. A 300 micro mol sample of the filtrate was transferred to an Eppendorf tube and an equal volume of sample dilution buffer (membraPure, Germany) was added. This solution was used for determining the concentrations of 7 amino acids (alanine, glutamine, glutamic acid, glycine, lysine, ornithine and taurine) using the A300 Amino Acid Analyzer (ARACUS, membraPure, Germany). Lactic acid concentrations were also measured using a dedicated plasma lactate determination kit and analyzer (LACT2, cobas, Roche Diagnostics GmbH, Germany). Concentrations of amino acids and lactic acid were expressed as micro mol/g wet weight.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Target follow-up
- 7 Days
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group 1: Calafiore cardioplegia | – | Other: Cardioplegic solutionPatients were randomly assigned to undergo surgery using one of two methods for myocardial protection: • Group 1: Calafiore intermittent antegrade warm blood cardioplegia (consisting of normothermic pump blood, potassium chloride 2 mEq/ml and magnesium sulfate 50%). This cardioplegic solution was administered at 37 degrees C following application of the aortic cross-clamp and repeated after completion of each distal coronary anastomosis as described previously. |
| Group 2: del Nido cardioplegia | – | Other: Cardioplegic solution• Group 2: Modified del Nido intermittent antegrade cold blood cardioplegic solution (consisting of 750 ml of lactated Ringer solution, 200 ml of pump blood, 13 ml of sodium bicarbonate 8.4%, 16 ml of mannitol 20%, 4 ml of magnesium sulfate 50%, 13 ml of lidocaine 2% and 13 ml of potassium chloride 2 mEq/ml). This solution was administered as a 1-liter bolus at 3-4 degrees C following application of the aortic cross-clamp, and repeated as a 500 ml bolus if cross-clamp time extended beyond 60 minutes (none of the patients in this study). |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Twenty consecutive patients undergoing elective primary coronary artery bypass grafting were enrolled in this study
Key inclusion criteria (1 listed)
- All consecutive patients undergoing elective primary coronary artery bypass grafting were enrolled in this study.
Key exclusion criteria (1 listed)
- Patients were excluded from this study if they had suffered from previous myocardial infarction, had reduced ejection fraction or were undergoing combined or repeated surgery.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cardioplegic solutionPatients were randomly assigned to undergo surgery using one of two methods for myocardial protection | Other | Group 1: Calafiore cardioplegia, Group 2: del Nido cardioplegia |
Primary outcome
Changes in markers of myocardial injury
Time frame: 4, 12, 24 and 48 hours postoperatively
Changes in release of myocardial CK-MB and troponin I
1 secondary outcome
Changes in myocardial amino acid concentrations
Time frame: 2-3 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Mar 2026.
- Individual participant dataSharing planned: Undecided. Data will be uploaded on (figshare) data repository site
Related trials for Myocardial Injury
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingPhase 2
Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction
Myocardial Infarction, Reperfusion Injury
Not yet recruitingObservational study
PAtient Similarity for Decision-Making in Prevention of Cardiovascular Toxicity (PACT): A Feasibility Study
Heart Failure, Coronary Artery Disease
Not yet recruitingPhase 2
Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI
No Reflow Phenomenon, Reperfusion Injuries, Myocardial
RecruitingObservational study
Mechanisms of Myocardial Injury and Ischemia in Patients With Rapid Atrial Fibrillation
Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mohammad Bashar Izzat study director
Damascus University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Myocardial Injury and Cardiac Surgery, run by Damascus University at 1 site in Syria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Syria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in markers of myocardial injury (time frame: 4, 12, 24 and 48 hours postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2026.